Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Autor: Mikol, Dd1, Barkhof, F, Chang, P, Coyle, Pk, Jeffery, Dr, Schwid, Sr, Stubinski, B, Uitdehaag, B, Ballario, Ch, Caceres, Fj, Correale, J, Cristiano, E, Garcea, Do, Leutic, Gg, Aicher, F, Barreira, Aa, Freedman, M, Grand'Maison, F, Jacques, F, Lee, L, Stefanelli, M, Edan, G, Pelletier, J, Berghoff, M, Keifer, R, Koehler, J, Hardiman, O, Comi, G, Mancardi, GIOVANNI LUIGI, Pozzilli, C, Trojano, Mp, Jongen, P, Uitdehaag, Bm, Belova, An, Boyko, An, Elchaninov, Ap, Kozlov, Va, Odinak, Mm, Shvarkov, Sb, Skoromets, Aa, Spirin, Nn, Stolyarov, Id, Vorobieva, Ov, Zavalishin, I, Arbizu, T, Fernandez, O, Izquierdo, G, Montalban, X, Goebels, N, Bates, D, Constantinescu, C, Turner, B, Bashir, K, Bever, Ct, Birnbaum, G, Brod, Sa, Carlini, W, Dunne, P, Elias, S, Estronza, N, Fox, E, Glyman, S, Gross, J, Guarnaccia, Jb, Gupta, A, Kaufman, M, Khan, O, Khatri, B, Kresa reahl, K, Lava, N, Leist, T, Markowitz, C, Mihai, C, Mikol, Dd, Miller, T, Panitch, H, Parry, G, Rammohan, Kw, Reder, A, Sheppard, C, Simsarian, Jp, Smiroldo, J, Spier, L, Thrower, B, Vollmer, T, Wendt, J, Wray, S, Wynn, D.

Publikováno v: Mikol, D D, Barkhof, F, Chang, P, Coyle, P K, Jeffery, D R, Schwid, S R, Stubinski, B & Uitdehaag, B M J 2008, ' Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial ', Lancet Neurology, vol. 7, no. 10, pp. 903-914 . https://doi.org/10.1016/S1474-4422(08)70200-X
Lancet Neurology, 7(10), 903-914. Lancet Publishing Group

Summary Background Interferon beta-1a and glatiramer acetate are commonly prescribed for relapsing-remitting multiple sclerosis (RRMS), but no published randomised trials have directly compared these two drugs. Our aim in the REGARD (REbif vs Glatira

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf18e8a5ef741d37534d0198c937a14
https://doi.org/10.1016/s1474-4422(08)70200-x

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

Autor: Petkau, AJ, White, RA, Ebers, GC, Reder, AT, Sibley, WA, Lublin, FD, Paty, DW, Duquette, P, Girard, M, Despault, L, DuBois, R, Knobler, RL, Kelley, L, Francis, GS, Lapierre, Y, Antel, J, Freedman, M, Hum, S, Greenstein, JI, Mishra, B, Muldoon, J, Whitaker, JN, Evans, BK, Layton, B, Laguna, J, Krikawa, J, Oger, JJ, Kastrukoff, LF, Moore, GRW, Hashimoto, SA, Morrison, W, Nelson, J, Goodin, DS, Massa, SM, Gutteridge, E, Arnason, BGW, Noronha, A, Martia, R, Rice, GPA, Lesaux, J, Johnson, KP, Panitch, HS, Bever, CT, Conway, K, Wallenberg, JC, Bedell, L, van den Noort, S, Weinshenker, B, Weiss, W, Reingold, S, Pachner, A, Taylor, W

Publikováno v: Multiple Sclerosis. 10(2)

We have analysed dataon exacerbation rates, Expanded Disability Status Scale (EDSS) scores, and lesion burdens using the results of two neutralizing antibody (NAB) assays (CPE and MxA) from the pivotal relapsing i/remitting multiple sclerosis (MS) tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e505dd19c0d8a072526a10982b50375
http://ora.ox.ac.uk/objects/uuid:1df9cc28-54d0-4335-9604-f62f8146dfc6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.